What happened
Shares of Odonate Therapeutics (NASDAQ: ODT) were soaring 23.1% as of 11:23 a.m. EDT on Friday. The drugmaker announced after the market closed on Thursday the pricing of a public offering of more than 5.6 million shares at $14.25 per share.
So what
Normally secondary stock offerings cause shares to fall, so why did Odonate Therapeutics stock rise? There could be a couple of factors at work.
Image source: Getty Images.
Odonate announced the stock offering on Wednesday. The price Odonate announced Thursday was only around 4% below the stock's closing price. Investors could have been bracing for a much lower offering price.
The biotech stock plunged more than 50% earlier this week after Odonate reported results from a phase 3 study evaluating tesetaxel in treating patients with metastatic breast cancer. The company stated that the drug, in combination with capecitabine, achieved its primary endpoint of improved progression-free survival. However, investors were concerned with tesetaxel's safety profile. It's quite possible that today's big jump stems from some investors buying the stock in the belief that the sell-off earlier this week has now run its course.
Now what
Odonate expects its public stock offering to close early next week and raise gross proceeds of around $80 million. The main thing to watch with the company is its progress toward obtaining FDA approval for tesetaxel. Odonate plans to file for FDA approval in mid-2021.
10 stocks we like better than Odonate Therapeutics, Inc.
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Odonate Therapeutics, Inc. wasn't one of them! That's right -- they think these 10 stocks are even better buys.
*Stock Advisor returns as of August 1, 2020
Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
